Serum glucose levels were increased with HFD/HF feeding, but were Tamoxifen datasheet similar in Xbp1−/− and Xbp1f/f mice. Hepatic triglycerides were also increased with HFD/HF feeding, but were significantly lower in Xbp1−/− compared to Xbp1f/f mice (55±10 vs 21 ±4 mg/g liver, p<0.02). Histology confirmed these findings. In vitro, PA induced expression

of the active spliced form of XBP1 (XBP1s) in Huh7/SCR, but not in Huh7/KD cells. Huh7/KD cells had increased CHOP gene expression compared to Huh7/SCR cells both at baseline and after PA treatment (p<0.05). PA-treated Huh7/KD cells had higher cytotoxicity compared to PA-treated Huh7/ SCR cells as measured by both LDH (p<0.01) and caspase 3/7 activity (p<0.05) assays. Conclusion: Hepatic Xbp1 deficiency increases liver injury in mice fed a HFD/HF diet. Huh7 cells with reduced XBP1 have enhanced injury induced by palmitic acid. We speculate that hepatic XBP1 may be a potential therapeutic target

for patients with NASH. Disclosures: The following people have nothing to disclose: Xiaoying Liu, Anne S. Henkel, Brian E. LeCuyer, Richard Green Background: Genetic modification and dietary challenges FK506 in vivo have been two major approaches to generate animal models of non-alcoholic fatty liver disease and its more severe form non-alcoholic steatohepatitis. However, these animal models rarely develop late stage diseases such as cirrhosis and hepato-cellular carcinoma within months. This study aimed to examine if disease progression is accelerated by combining genetic and diet-induced dyslipidemia in rodents and if the model exhibits more severe conditions compared to other animal models. Methods: Male low-density lipoprotein receptor knockout (LDLR-KO) mice were fed a normal chow or choline-deficient amino acid-defined diet including 1 w/w% cholesterol and 41 kcal% fat, i.e. modified CDAA diet. Separate groups of animals were under the diet for 1, 4, 8, 16, 24 or 31

weeks. Blood biochemistry, hepatic inflammatory and fibrotic gene expression analyses, histopathology, and immunohistochem-istry were conducted. Results: Plasma hepatic transaminase levels increased 1 week after the diet-feeding and showed the highest level in the 4 weeks group, which Cobimetinib nmr gradually decreased thereafter. Microvesicular and macrovesicular steatosis in the liver were observed from 1 week. The macrovesicular steatosis was exacerbated over time and was observed in almost all hepatocytes after 8 weeks. Inflammatory cell infiltration was observed from 1 week, reached the highest level after 4 weeks, and remained throughout the study. The infiltrated cells were mainly composed of F4/80-positive macrophages and MPO-positive neutrophils and monocytes. Desmin-positive hepatic stellate cells and α-SMA-positive activated stellate cells were increased by 8 weeks. Hepatic fibrosis area stained with Sirius red was increased after 4 weeks and spread all over the liver over time.